BNZPF (Biosenic) Short-Term Debt : $3.31 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Biosenic Short-Term Debt?

Biosenic's Short-Term Debt for the quarter that ended in Jun. 2024 was $3.31 Mil.

Biosenic's quarterly Short-Term Debt increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($12.50 Mil) but then declined from Dec. 2023 ($12.50 Mil) to Jun. 2024 ($3.31 Mil).

Biosenic's annual Short-Term Debt increased from Dec. 2021 ($0.38 Mil) to Dec. 2022 ($8.24 Mil) and increased from Dec. 2022 ($8.24 Mil) to Dec. 2023 ($12.50 Mil).

Biosenic Short-Term Debt Historical Data

The historical data trend for Biosenic's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Short-Term Debt Chart

Biosenic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

2.81

3.70

0.38

8.24

12.50

Biosenic Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Short-Term Debt	Get a 7-Day Free Trial															5.07	8.24	-	12.50	3.31

Biosenic Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biosenic Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biosenic's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (GREY:BNZPF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

0R55:UK BT1:Germany BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic Headlines

From GuruFocus

Q2 2021 Bone Therapeutics SA Earnings Call Transcript

By GuruFocus Research • 03-03-2024